Operator of a digital medicine company intended to provide insights on laboratory test results that are understandable to patients. The company fosters the interactions between laboratories, health professionals and patients and goes beyond results in patient care through the use of new technologies and artificial intelligence, enabling medical professionals to easily interpret and diagnose in a personalized and effective way.
Developer of antibody-based therapeutics intended to provide a new approach to treating fibrosis. The company engages in the development of therapeutics that target key fibrotic mediator proteins that aid in the development of fibrosis in chronically damaged organs, enabling medical practitioners to halt and reverse critical fibrosis and associated conditions.
Inspirna is a biopharmaceutical company focused on discovering and developing innovative therapeutic targets and drugs for various cancer subtypes, including melanoma, colorectal cancer, and triple-negative breast cancer. Utilizing a proprietary microRNA-based target discovery platform, Inspirna identifies and validates novel post-transcriptionally regulated targets, leading to the creation of first-in-class therapeutics. The company has developed several promising drug candidates, such as RGX-104, an oral small molecule designed for treating solid tumors, RGX-202, which targets cancer metabolism in gastrointestinal cancers, and RGX-019, a monoclonal antibody aimed at disrupting pathways that promote tumor progression and metastasis. Founded in 2010 and headquartered in New York, Inspirna strives to transform the lives of cancer patients by providing safe and effective therapies for metastatic disease.
Biosyntia ApS is a biotechnology company based in Hørsholm, Denmark, founded in 2012. The company specializes in developing biocatalysts for the fermentation of complex chemical compounds, such as flavors, fragrances, active pharmaceutical ingredients (APIs), pigments, and additives. Utilizing its innovative, patent-pending high-throughput screening technology, Biosyntia accelerates the development of these biocatalysts, aiming to enhance efficiency and reduce production costs. By focusing on biocatalysis, the company offers a more sustainable alternative to traditional chemical synthesis, significantly lowering environmental impacts. Biosyntia collaborates with manufacturers to create tailored fermentation processes that promote greener manufacturing practices in the fine chemicals industry.
LimFlow is a developer of innovative peripheral endovascular technology aimed at treating end-stage chronic limb ischemia (CLI) patients. The LimFlow System uses a novel, ultrasound-guided percutaneous procedure to divert blood around diseased arteries into the tibial vein, effectively supplying oxygenated blood to the ischemic foot. This approach offers new hope to patients who have exhausted other revascularization options. By restoring blood flow, the system alleviates ischemic pain, promotes wound healing, reduces the risk of amputations, and helps restore mobility. Currently, the LimFlow System is approved for sale in markets regulated by the CE Mark, while in the United States, it remains an investigational device limited to research use.
HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment. The company's platform helps to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery enabling patients to get treatment against several diseases.
Synthace Limited is a company that develops software and processes aimed at enhancing productivity in biosciences across various industries, including health, pharmaceuticals, food, energy, agri-science, and manufacturing. Central to its offerings is Antha, a cloud-based platform designed to automate and improve biological processes. Antha allows users to visually design, execute, and analyze biological workflows, linking lab equipment, protocols, and processes to enable repeatable and efficient development. Founded in 2011 and headquartered in London, with an additional location in Cambridge, Massachusetts, Synthace also maintains a strategic partnership with Microsoft to further its mission of increasing bioscience productivity and facilitating better engineering of biological systems.
Nitrase Therapeutics is a biopharmaceutical company focused on discovering and developing drugs targeting a newly identified class of enzymes known as Nitrases. Initially concentrating on Parkinson’s disease, Nitrase aims to create therapies that may slow or halt the progression of this neurodegenerative condition. Beyond its primary focus, the company plans to expand its research to address other aging-related diseases, including Type II diabetes, heart disease, and various cancer types. Founded in 2012 and headquartered in Jackson, Wyoming, with additional facilities in San Francisco, California, Nitrase Therapeutics is positioned to contribute significantly to the treatment of complex diseases associated with aging.
Developer of disease-modifying therapies designed to focus on developing novel immune engagers. The company offers CD8 T-cell immune modulators for the treatment of autoimmune diseases as well as it specifically targets a subset of t-lymphocytes to delay the onset and ameliorate targeted autoimmune diseases, enabling doctors to administer state-of-the-art drugs for treating autoimmune disorders in patients.
Operater of a cell therapy company intended to develop novel cell therapies for patients with solid tumors and no treatment options. The company specializes in the development of CAR T-cell therapies that produce a better and more durable response than previous CAR T generations, enabling healthcare professionals to improve treatment outcomes and save the lives of patients with refractory cancers.
CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, founded in 2018. The company specializes in the development of treatments for cardiovascular, metabolic, and kidney diseases. Its primary focus is on CIN-107, a novel aldosterone synthase inhibitor aimed at addressing resistant hypertension and primary aldosteronism. By advancing its promising clinical candidates, CinCor Pharma seeks to gain marketing approval for innovative therapies that can effectively address unmet medical needs in these critical areas of health.
iOmx Therapeutics AG is a Munich-based company specializing in immuno-oncology target discovery and drug development. The company focuses on creating innovative cancer therapeutics that target novel immune checkpoint modulators present on tumor cells. By employing a systematic screening approach of human tumor cells, iOmx has identified several new targets and studied their mechanisms of action. The foundation of its research is based on the principles of cancer immune-checkpoint therapy, which aims to overcome the natural resistance of tumors to immune responses. This resistance is often facilitated by cell surface molecules that activate immune-inhibitory receptors on T cells. By neutralizing these inhibitory interactions, iOmx Therapeutics seeks to reactivate the host immune response, thereby enhancing the effectiveness of cancer treatments.
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid development and the commercialization of revolutionary biodegradable sealants and adhesives for wound closure in the field of surgery, with a key focus on minimally invasive surgery. TISSIUM is developing products that are non-toxic, bind strongly to tissues and deliver ‘on-demand’ wound closure within the ‘wet’ and dynamic environments in the body. The Company’s technology and products are based on world-class research and intellectual property from the laboratories of Robert Langer (MIT) and Jeff Karp (Brigham & Women’s Hospital). Gecko was founded in 2013 and is backed by leading healthcare investors Omnes Capital, CM-CIC and CapDecisif Manangement.
Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer treatments that target DNA damage response (DDR) pathways. Founded in 2015, the company aims to create first-in-class therapies that selectively kill cancer cells by exploiting the mechanisms involved in DNA repair. Its product pipeline features several promising candidates, including DNA polymerase theta (Polθ) and an in-licensed program targeting a novel DDR protein. Artios collaborates with Cancer Research Technology and leading researchers in the field to advance its development efforts. The company's leadership comprises experts with extensive experience in DDR drug discovery, and it has garnered investment from notable entities, including SV Life Sciences and AbbVie Ventures.
Operator of a biopharmaceutical company intended to discover and develop therapies that slow or stop the progression of neurodegenerative diseases. The company engages in identifying new medicines to preserve cognition and other brain functions and enhance resilience to neurodegenerative diseases including Alzheimer's, Frontotemporal Dementia, and Parkinson's, enabling people suffering from neurodegenerative diseases to access suitable therapeutics for fast recovery.
AAVantgarde Bio is focused on developing innovative gene therapies specifically for inherited retinal disorders. The company utilizes proprietary Adeno-Associated Viral (AAV) vector platforms to overcome the limitations associated with the cargo capacity of traditional AAV vectors. This technology allows for the delivery of larger genes to both ocular and non-ocular tissues, enhancing the potential for effective treatment in patients. By addressing these challenges, AAVantgarde Bio aims to advance the field of gene therapy and improve outcomes for individuals affected by genetic eye diseases.
Alia Therapeutics is developing next-generation gene-editing medicines to cure rare genetic diseases.
Borea Therapeutics is advancing a new generation of gene therapies that would enable the targeting of specific tissues and cells.
Operator of a drug discovery platform designed to develop immune based therapies, including powerful cell therapies, that create accessible cures for solid tumors and blood cancers. The company's platform offers leveraging epigenetic variation and CAR-T precision genetic engineering technology to target tumorous epitopes that are broadly represented across various cancers, enabling patients to get allogeneic treatments to overcome disease.
Private Equity Round in 2021
Mainstay Medical Holdings plc is a medical device company based in Dublin, Ireland, with operations in the United States and Australia. Founded in 2008, the company specializes in developing and commercializing ReActiv8, an implantable neurostimulation system aimed at treating chronic low back pain. This innovative therapy is designed to restore control to the muscles that stabilize the lumbar spine, addressing a significant unmet need in the healthcare market. By collaborating with scientists and clinical experts, Mainstay Medical focuses on delivering effective solutions for patients suffering from debilitating pain, ultimately enhancing their quality of life.
Noema Pharma is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts aim to address the most disabling symptoms associated with conditions such as Tuberculosis Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By prioritizing patient needs, Noema Pharma seeks to create effective treatments that significantly improve the quality of life for individuals suffering from these challenging conditions.
Catamaran Bio, Inc. develops CAR-NK immune cell therapies for the treatment of tumor. The company develops Tailwind platform to engineer, expand, and process NK cells into allogenic CAR-NK cell therapy shelf products. Catamaran Bio, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.
Myricx Bio is a drug discovery company based in Stevenage, United Kingdom, that specializes in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT). Founded in 2019, the company focuses primarily on oncology while also exploring applications in other diseases such as inflammatory conditions, epilepsy, and Alzheimer’s disease. By targeting N-myristoyl transferase, Myricx Bio aims to unlock new therapeutic potentials, providing precision medicines that can specifically kill cancer cells and address viral infections. Through its innovative approach, the company seeks to deliver effective treatments for a diverse range of health conditions.
GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, specializing in the discovery and development of gene therapy treatments for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. The company utilizes two primary technology platforms: mitochondrial targeting sequences and optogenetics, aiming to preserve or restore vision in patients affected by severe retinal diseases. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III clinical trials for treating Leber hereditary optic neuropathy associated with ND4 gene mutations, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. Additionally, GenSight is advancing various preclinical programs targeting both ophthalmic and neurodegenerative conditions, reflecting its commitment to innovative solutions for patients with significant vision impairment or blindness. GenSight Biologics was founded in 2012.
Polyneuron Pharmaceuticals AG is focused on developing innovative therapeutics for the treatment of antibody-mediated autoimmune disorders. The company is working on several drug candidates, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron utilizes a platform technology called Antibody-Catch, which is based on biodegradable glycopolymers. This technology selectively targets and eliminates pathological autoantibodies while preserving the integrity of the rest of the immune system. Founded in 2014 and headquartered in Basel, Switzerland, Polyneuron aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system.
Enthera S.r.l. is an Italian biotechnology company established in 2016, based in Milan, and operates as a subsidiary of BiovelocITA S.r.l. The company focuses on developing innovative biologics aimed at treating diabetes and its related gastrointestinal complications, particularly enteropathy, as well as other intestinal disorders that share similar biological pathways. Enthera's research is centered on monoclonal antibody discovery and biotherapeutics that target mechanisms involved in cell apoptosis in the gut, pancreas, and other organs. By addressing these pathways, Enthera aims to provide effective treatments for underserved autoimmune conditions, thereby contributing to advancements in the management of type 1 diabetes and inflammatory bowel disease. The company's name reflects its mission, combining the terms "entero," relating to the intestine, and "therapy."
MISSION Therapeutics Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small-molecule drugs that selectively target deubiquitylating enzymes (DUBs). The company's pipeline includes promising candidates such as USP30, which is aimed at treating Parkinson's disease and cancer, and USP7, which is recognized as a significant target in oncology. In addition to these, MISSION Therapeutics has various DUB programs that address conditions in oncology, neurodegeneration, rare mitochondrial diseases, kidney disease, and inflammation. Founded in 2011, the company is actively engaged in advancing its innovative drug development platform, which capitalizes on the ubiquitin pathway to enhance protein homeostasis and offers potential therapeutic options in several challenging medical areas.
NodThera Limited is a biotechnology company focused on researching and developing novel inhibitors of the NLRP3 inflammasome, which play a critical role in inflammatory and neuroinflammatory diseases. Established in 2016 and headquartered in Little Chesterford, United Kingdom, NodThera operates a laboratory in Seattle, Washington, and a corporate office in Lexington, Massachusetts. The company aims to create therapies targeting a range of conditions including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. By developing potent and selective NLRP3 inflammasome inhibitors, NodThera seeks to reduce pro-inflammatory cytokines, enabling more effective treatment options for patients suffering from chronic inflammation-related diseases.
HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment. The company's platform helps to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery enabling patients to get treatment against several diseases.
PinCell is a biotech company focused on the research of therapeutic molecules based on new targets related to the pathomechanisms of inflammatory and neoplastic skin diseases.
Genespire is a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases.
Epsilen Bio Srl is a Milan-based biotechnology company focused on developing innovative therapies for patients with underserved medical conditions. Founded in December 2019, the company specializes in a transformative approach known as epigenetic silencing, which targets and stabilizes the genomic silencing of genes implicated in various pathological processes. By leveraging this platform, Epsilen Bio aims to provide healthcare professionals with new therapeutic options to address significant medical needs.
Nitrase Therapeutics is a biopharmaceutical company focused on discovering and developing drugs targeting a newly identified class of enzymes known as Nitrases. Initially concentrating on Parkinson’s disease, Nitrase aims to create therapies that may slow or halt the progression of this neurodegenerative condition. Beyond its primary focus, the company plans to expand its research to address other aging-related diseases, including Type II diabetes, heart disease, and various cancer types. Founded in 2012 and headquartered in Jackson, Wyoming, with additional facilities in San Francisco, California, Nitrase Therapeutics is positioned to contribute significantly to the treatment of complex diseases associated with aging.
Pi-Cardia is a medical device start-up focused on developing an innovative catheter designed to treat aortic stenosis. The company’s proprietary technology utilizes a low-profile trans-femoral catheter that incorporates nitinol elements to deliver mechanical impact, creating fractures in calcified heart valves without damaging the surrounding soft tissues. This procedure, which takes only a few seconds, aims to increase the effective orifice area of the valve, providing a less invasive alternative to valve replacement. Pi-Cardia's approach seeks to offer a cost-effective and durable treatment option for patients suffering from this condition.
RefleXion Medical Inc. specializes in developing a biologically-guided radiotherapy system aimed at transforming cancer treatment. The company’s innovative technology allows tumors to continuously signal their location during therapy, facilitating the simultaneous treatment of multiple tumors, particularly in cases of metastasis. The RefleXion X1 machine is currently cleared for various forms of radiotherapy, including stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT). At the core of RefleXion's approach is the integration of positron-emission tomography (PET) imaging, which enables real-time tumor tracking and dose adaptation based on the biological characteristics of the tumors. This advancement in radiotherapy promises to enhance precision in cancer treatment, offering a potential paradigm shift in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic collaborations, including partnerships with Telix Pharmaceuticals and HealthMyne.
Redx Pharma is a UK-based drug discovery and development company founded in 2010, focusing on creating innovative small molecule drugs aimed at treating cancer, fibrosis, and other unmet medical needs. The company is advancing several key drug candidates, including RXC004, a porcupine inhibitor in Phase I clinical trials for various cancers, and a ROCK inhibitor targeting inflammatory diseases related to fibrosis. Other notable developments include a Rho-associated protein kinase 2 inhibitor for diabetic nephropathy and idiopathic pulmonary fibrosis, along with a Pan-RAF inhibitor and SHP2 for cancer treatment. Additionally, Redx Pharma collaborates with Jazz Pharmaceuticals to explore drug candidates targeting the Ras/Raf/MAP kinase pathway. The company operates through three subsidiaries: Redx Oncology, Redx Anti-Infectives, and Redx Immunology, and has established partnerships with major pharmaceutical firms and the NHS to enhance its research and development efforts.
Inventiva S.A. is a biopharmaceutical company based in Daix, France, specializing in the development of oral small molecule therapies targeting significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company's lead candidate, Lanifibranor, is currently in Phase IIb clinical trials for the treatment of nonalcoholic steatohepatitis. Additionally, Inventiva is advancing Odiparcil, in Phase IIa trials for mucopolysaccharidosis type VI, and has several preclinical programs, including potential treatments for malignant mesothelioma and lung cancer. The company's research and development efforts are supported by a proprietary library of molecules and a team experienced in targeting nuclear receptors and transcription factors. Inventiva has established partnerships with prominent organizations, including the Institut Curie for oncology research and AbbVie for autoimmune disease treatments. Founded in 2011, the company continues to focus on innovative solutions for complex medical conditions.
Chroma Medicine is a genomic medicine company focused on epigenetic editing to transform the treatment of genetically driven diseases. By leveraging epigenetics, which regulates gene expression naturally, Chroma Medicine aims to develop innovative therapies that provide precise control over gene activity. The company utilizes programmable epigenetic editors that combine DNA binding domains with epigenetic effector domains, allowing for targeted manipulation of genes and chromatin structure. This approach promises to create a new class of therapeutics that offers unparalleled control over gene expression, potentially leading to more effective treatments for a range of genetic disorders.
GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, specializing in the discovery and development of gene therapy treatments for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. The company utilizes two primary technology platforms: mitochondrial targeting sequences and optogenetics, aiming to preserve or restore vision in patients affected by severe retinal diseases. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III clinical trials for treating Leber hereditary optic neuropathy associated with ND4 gene mutations, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. Additionally, GenSight is advancing various preclinical programs targeting both ophthalmic and neurodegenerative conditions, reflecting its commitment to innovative solutions for patients with significant vision impairment or blindness. GenSight Biologics was founded in 2012.
DMC Biotechnologies, Inc. is a biotechnology company based in Boulder, Colorado, focused on developing bio-based products through microbial fermentation technology. The company specializes in the production of specialty chemicals, flavors, fragrances, nutraceuticals, and pharmaceuticals. By utilizing Dynamic Metabolic Control technology, DMC aims to streamline the production process, reducing both costs and development timelines from discovery to commercial viability. Founded in 2014, DMC Biotechnologies is dedicated to creating sustainable manufacturing solutions that utilize lower energy and resources, contributing to a more sustainable economy.
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid development and the commercialization of revolutionary biodegradable sealants and adhesives for wound closure in the field of surgery, with a key focus on minimally invasive surgery. TISSIUM is developing products that are non-toxic, bind strongly to tissues and deliver ‘on-demand’ wound closure within the ‘wet’ and dynamic environments in the body. The Company’s technology and products are based on world-class research and intellectual property from the laboratories of Robert Langer (MIT) and Jeff Karp (Brigham & Women’s Hospital). Gecko was founded in 2013 and is backed by leading healthcare investors Omnes Capital, CM-CIC and CapDecisif Manangement.
Inventiva S.A. is a biopharmaceutical company based in Daix, France, specializing in the development of oral small molecule therapies targeting significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company's lead candidate, Lanifibranor, is currently in Phase IIb clinical trials for the treatment of nonalcoholic steatohepatitis. Additionally, Inventiva is advancing Odiparcil, in Phase IIa trials for mucopolysaccharidosis type VI, and has several preclinical programs, including potential treatments for malignant mesothelioma and lung cancer. The company's research and development efforts are supported by a proprietary library of molecules and a team experienced in targeting nuclear receptors and transcription factors. Inventiva has established partnerships with prominent organizations, including the Institut Curie for oncology research and AbbVie for autoimmune disease treatments. Founded in 2011, the company continues to focus on innovative solutions for complex medical conditions.
Inotrem S.A. is a biotechnology company based in Paris, France, specializing in the discovery and development of innovative treatments for inflammatory pathologies, particularly in critical care settings. Founded in 2013, the company focuses on immunotherapy and has created a novel immunomodulation approach targeting the TREM-1 pathway to manage excessive inflammation. Its lead product, nangibotide (also known as LR12), is a first-in-class TREM-1 inhibitor designed to address severe conditions such as septic shock and myocardial infarction. Inotrem is also advancing a program aimed at treating chronic inflammatory diseases, leveraging its proprietary technology platform to develop new therapeutic modalities.
Biotalys is a green biotech company that employs its proprietary Agrobody technology platform to develop crop protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combine the high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications. It was incorporated in 2012 and is based in Ghent, Belgium.
Abivax is a clinical-stage biotechnology company based in Paris, France, dedicated to discovering and optimizing treatments for inflammatory diseases, viral infections, and cancer. The company is primarily focused on its lead product, ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis and Crohn’s Disease, as well as for COVID-19. Additionally, ABX464 is being evaluated in Phase IIa trials for rheumatoid arthritis and has completed Phase IIa trials aimed at achieving viral remission in HIV patients. Abivax is also developing ABX 196, an immune enhancer in Phase 1/2 trials for hepatocellular cancer, and ABX 544, a candidate for Ebola treatment based on polyclonal antibodies. Furthermore, the company is conducting research into treatments for Dengue fever, influenza, and respiratory syncytial virus. Abivax collaborates with institutions such as the French National Centre for Scientific Research and the University of Montpellier. Founded in 2013, the company aims to harness the body’s immune response to manage chronic inflammatory conditions effectively.
AFYX Therapeutics A/S is a pharmaceutical company based in Copenhagen, Denmark, specializing in the development and manufacturing of treatments for mucosal diseases. Founded in 2014 and formerly known as Dermtreat ApS, the company focuses on addressing conditions that currently lack approved therapies. Its flagship product, the Rivelin®-CLO patch, is designed for the treatment of oral lichen planus. This innovative patch is flexible, biodegradable, and adheres to mucosal surfaces, utilizing electrospinning technology to deliver therapeutic agents directly to affected areas. The design of the patch allows for effective treatment without disrupting patients’ daily activities, thereby facilitating recovery from mucosal lesions.
Comet Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2018. It specializes in developing novel small-molecule treatments targeting various diseases, particularly orphan neurological disorders. The company's core innovation is its CoEnzyme metabolism platform, which aims to restore dysregulated CoEnzyme A metabolism. This therapeutic approach enables healthcare providers to address significant unmet medical needs in the treatment of these complex conditions.
CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, founded in 2018. The company specializes in the development of treatments for cardiovascular, metabolic, and kidney diseases. Its primary focus is on CIN-107, a novel aldosterone synthase inhibitor aimed at addressing resistant hypertension and primary aldosteronism. By advancing its promising clinical candidates, CinCor Pharma seeks to gain marketing approval for innovative therapies that can effectively address unmet medical needs in these critical areas of health.
Twentyeight-Seven, Inc. is a biotechnology company based in Watertown, Massachusetts, specializing in the development of small molecules that modulate microRNAs (miRNAs) by targeting the proteins that interact with these molecules. Their innovative approach focuses on using short non-coding RNAs to inhibit gene expression, suppress mRNA translation, and promote mRNA decay. By targeting miRNAs that play a critical role in cancer initiation, progression, and metastasis, Twentyeight-Seven aims to create effective therapeutic solutions for cancer treatment.
Polyneuron Pharmaceuticals AG is focused on developing innovative therapeutics for the treatment of antibody-mediated autoimmune disorders. The company is working on several drug candidates, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron utilizes a platform technology called Antibody-Catch, which is based on biodegradable glycopolymers. This technology selectively targets and eliminates pathological autoantibodies while preserving the integrity of the rest of the immune system. Founded in 2014 and headquartered in Basel, Switzerland, Polyneuron aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system.
GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, specializing in the discovery and development of gene therapy treatments for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. The company utilizes two primary technology platforms: mitochondrial targeting sequences and optogenetics, aiming to preserve or restore vision in patients affected by severe retinal diseases. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III clinical trials for treating Leber hereditary optic neuropathy associated with ND4 gene mutations, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. Additionally, GenSight is advancing various preclinical programs targeting both ophthalmic and neurodegenerative conditions, reflecting its commitment to innovative solutions for patients with significant vision impairment or blindness. GenSight Biologics was founded in 2012.
HighLife SAS is a medtech company that specializes in developing a novel transcatheter mitral valve replacement system aimed at treating patients with mitral regurgitation. Founded in 2010 and headquartered in Paris, France, with an additional office in Irvine, California, the company focuses on providing a minimally invasive prosthetic mitral valve that can be implanted on a beating heart. This approach preserves the native valve structure and respects the surrounding anatomy, ensuring reduced trauma during surgical procedures. HighLife's technology is designed for ease and safety of use, as well as optimal treatment outcomes, allowing for delivery through a transseptal passage via the femoral vein. The system is currently undergoing clinical evaluation to assess its effectiveness in addressing severe heart conditions.
Checkmate Pharmaceuticals is a clinical-stage biotechnology company based in Cambridge, Massachusetts, that specializes in developing novel immunotherapies for cancer treatment. Founded in 2015, the company focuses on leveraging CpG oligonucleotides to enhance anti-tumor T-cell responses and overcome the mechanisms that allow tumors to evade immune detection. By combining its proprietary technology with checkpoint inhibition, Checkmate aims to improve the efficacy of existing immunotherapies and provide new treatment options for patients. The company has formed strategic alliances with major pharmaceutical firms, including Merck KGaA and Pfizer, to further its research and development efforts in the field of cancer immunotherapy.
Shockwave Medical, Inc. is a medical device company that specializes in intravascular lithotripsy technology aimed at treating calcified plaque in patients with various cardiovascular diseases. The company has developed the Lithoplasty™ family of balloon dilatation catheters, which incorporate lithotripsy electrodes to enhance the compliance of rigid vascular and valvular lesions before low-pressure dilation. This approach minimizes injury to healthy tissue and addresses limitations associated with traditional revascularization technologies. Shockwave offers specific catheters for different applications, including M5 catheters for above-the-knee peripheral artery disease, C2 catheters for coronary artery disease, and S4 catheters for below-the-knee peripheral artery disease. The technology is designed to facilitate more effective angioplasty and improve stent delivery, as well as enhance native tissue preparation for trans-catheter aortic valve replacement. Founded in 2009 and headquartered in Santa Clara, California, Shockwave Medical serves interventional cardiologists, vascular surgeons, and interventional radiologists across the United States and internationally.
InCarda Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops transformative therapies for cardiovascular diseases that enable patients to use in the first moments of acute cardiovascular symptoms. The company develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. InCarda Therapeutics, Inc. was formerly known as Pleiades Cardio-Therapeutics, Inc. and changed its name to InCarda Therapeutics, Inc. in May 2011. The company was founded in 2009 and is based in Newark, California.
Inspirna is a biopharmaceutical company focused on discovering and developing innovative therapeutic targets and drugs for various cancer subtypes, including melanoma, colorectal cancer, and triple-negative breast cancer. Utilizing a proprietary microRNA-based target discovery platform, Inspirna identifies and validates novel post-transcriptionally regulated targets, leading to the creation of first-in-class therapeutics. The company has developed several promising drug candidates, such as RGX-104, an oral small molecule designed for treating solid tumors, RGX-202, which targets cancer metabolism in gastrointestinal cancers, and RGX-019, a monoclonal antibody aimed at disrupting pathways that promote tumor progression and metastasis. Founded in 2010 and headquartered in New York, Inspirna strives to transform the lives of cancer patients by providing safe and effective therapies for metastatic disease.
Sitryx Therapeutics is a biopharmaceutical company established in 2018 and based in Oxford, United Kingdom. It focuses on developing disease-modifying therapeutics in the fields of immuno-oncology and immuno-inflammation by regulating cell metabolism. The company aims to correct and alter immune cell functions to inhibit tumor growth. Co-founded by renowned scientists from the United States and Europe, Sitryx has garnered significant funding, including a $30 million Series A round from various specialist investors. The company is actively engaged in multiple stages of drug discovery, working on a diverse pipeline of projects aimed at addressing unmet medical needs in immunometabolism.
Enthera S.r.l. is an Italian biotechnology company established in 2016, based in Milan, and operates as a subsidiary of BiovelocITA S.r.l. The company focuses on developing innovative biologics aimed at treating diabetes and its related gastrointestinal complications, particularly enteropathy, as well as other intestinal disorders that share similar biological pathways. Enthera's research is centered on monoclonal antibody discovery and biotherapeutics that target mechanisms involved in cell apoptosis in the gut, pancreas, and other organs. By addressing these pathways, Enthera aims to provide effective treatments for underserved autoimmune conditions, thereby contributing to advancements in the management of type 1 diabetes and inflammatory bowel disease. The company's name reflects its mission, combining the terms "entero," relating to the intestine, and "therapy."
HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment. The company's platform helps to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery enabling patients to get treatment against several diseases.
NodThera Limited is a biotechnology company focused on researching and developing novel inhibitors of the NLRP3 inflammasome, which play a critical role in inflammatory and neuroinflammatory diseases. Established in 2016 and headquartered in Little Chesterford, United Kingdom, NodThera operates a laboratory in Seattle, Washington, and a corporate office in Lexington, Massachusetts. The company aims to create therapies targeting a range of conditions including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. By developing potent and selective NLRP3 inflammasome inhibitors, NodThera seeks to reduce pro-inflammatory cytokines, enabling more effective treatment options for patients suffering from chronic inflammation-related diseases.
Biosyntia ApS is a biotechnology company based in Hørsholm, Denmark, founded in 2012. The company specializes in developing biocatalysts for the fermentation of complex chemical compounds, such as flavors, fragrances, active pharmaceutical ingredients (APIs), pigments, and additives. Utilizing its innovative, patent-pending high-throughput screening technology, Biosyntia accelerates the development of these biocatalysts, aiming to enhance efficiency and reduce production costs. By focusing on biocatalysis, the company offers a more sustainable alternative to traditional chemical synthesis, significantly lowering environmental impacts. Biosyntia collaborates with manufacturers to create tailored fermentation processes that promote greener manufacturing practices in the fine chemicals industry.
Crescendo Biologics Limited is a Cambridge-based company focused on developing innovative therapies for oncology and dermatology, particularly through small molecules and monoclonal antibodies. The company specializes in multi-specific immune-oncology modulators and Humabody Drug Conjugates, leveraging a proprietary transgenic mouse platform that facilitates the in vivo maturation of human VH domains. This technology allows Crescendo to optimize the affinity and biophysical properties of its Humabodies, which are small antibody fragments retaining essential binding capabilities. By addressing challenges in generating high-affinity, soluble human VH antibody fragments, Crescendo aims to develop potent, multi-functional therapeutics. The company engages in both in-house product development and partnerships with other organizations to expand its impact in the field of antibody therapeutics. Established in 2007, Crescendo Biologics was originally named Translocus Limited before rebranding in 2009.
Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, focused on developing precision therapies for cardiovascular and renal conditions. Established in 2014, the company operates as a subsidiary of Novo Nordisk A/S. Corvidia specializes in researching and commercializing innovative treatments for chronic kidney disease, atherosclerotic cardiovascular disease, inflammation, and high triglyceride-induced acute pancreatitis. By identifying patients with unique sensitivities to specific biological pathways, Corvidia aims to advance the development of transformative therapies that address the complex interplay between cardiovascular and renal health.
EryDel S.p.A., based in Urbino, Italy, specializes in the production and commercialization of innovative drug delivery systems utilizing autologous erythrocytes, or red blood cells. Founded in 2007, the company has developed patented technology that allows for the efficient loading of red blood cells with various therapeutic agents, including drugs and proteins. This approach enables a gradual release of these agents into the patient's body, enhancing treatment efficacy while minimizing side effects. The technology is particularly beneficial for managing chronic conditions, offering a potential alternative to daily treatments through monthly transfusions of specially loaded blood. EryDel's offerings include a red cell loader and disposable kits to support the drug delivery process. The company's solutions have been tested in treating Inflammatory Bowel Diseases (IBDs) such as ulcerative colitis and Crohn's disease, and it aims to improve the management of other rare diseases through its innovative therapies.
LimFlow is a developer of innovative peripheral endovascular technology aimed at treating end-stage chronic limb ischemia (CLI) patients. The LimFlow System uses a novel, ultrasound-guided percutaneous procedure to divert blood around diseased arteries into the tibial vein, effectively supplying oxygenated blood to the ischemic foot. This approach offers new hope to patients who have exhausted other revascularization options. By restoring blood flow, the system alleviates ischemic pain, promotes wound healing, reduces the risk of amputations, and helps restore mobility. Currently, the LimFlow System is approved for sale in markets regulated by the CE Mark, while in the United States, it remains an investigational device limited to research use.
Inventiva S.A. is a biopharmaceutical company based in Daix, France, specializing in the development of oral small molecule therapies targeting significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company's lead candidate, Lanifibranor, is currently in Phase IIb clinical trials for the treatment of nonalcoholic steatohepatitis. Additionally, Inventiva is advancing Odiparcil, in Phase IIa trials for mucopolysaccharidosis type VI, and has several preclinical programs, including potential treatments for malignant mesothelioma and lung cancer. The company's research and development efforts are supported by a proprietary library of molecules and a team experienced in targeting nuclear receptors and transcription factors. Inventiva has established partnerships with prominent organizations, including the Institut Curie for oncology research and AbbVie for autoimmune disease treatments. Founded in 2011, the company continues to focus on innovative solutions for complex medical conditions.
RefleXion Medical Inc. specializes in developing a biologically-guided radiotherapy system aimed at transforming cancer treatment. The company’s innovative technology allows tumors to continuously signal their location during therapy, facilitating the simultaneous treatment of multiple tumors, particularly in cases of metastasis. The RefleXion X1 machine is currently cleared for various forms of radiotherapy, including stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT). At the core of RefleXion's approach is the integration of positron-emission tomography (PET) imaging, which enables real-time tumor tracking and dose adaptation based on the biological characteristics of the tumors. This advancement in radiotherapy promises to enhance precision in cancer treatment, offering a potential paradigm shift in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic collaborations, including partnerships with Telix Pharmaceuticals and HealthMyne.
Mainstay Medical Holdings plc is a medical device company based in Dublin, Ireland, with operations in the United States and Australia. Founded in 2008, the company specializes in developing and commercializing ReActiv8, an implantable neurostimulation system aimed at treating chronic low back pain. This innovative therapy is designed to restore control to the muscles that stabilize the lumbar spine, addressing a significant unmet need in the healthcare market. By collaborating with scientists and clinical experts, Mainstay Medical focuses on delivering effective solutions for patients suffering from debilitating pain, ultimately enhancing their quality of life.
Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immune-therapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company's key platforms, Vaxwave and TheraT, aim to elicit robust immune responses, including high levels of neutralizing antibodies and T cells, which are often lacking in traditional therapies. Hookipa's product pipeline features HB-101, a vaccine targeting cytomegalovirus, and HB-201 and HB-202, which are in preclinical studies for human papillomavirus-positive cancers. Additionally, the company is collaborating with Gilead Sciences to create therapies for chronic Hepatitis B and HIV infections. Founded in 2011 and headquartered in New York, Hookipa Pharma aims to transform the field of immunotherapy through its innovative approaches.
HighLife SAS is a medtech company that specializes in developing a novel transcatheter mitral valve replacement system aimed at treating patients with mitral regurgitation. Founded in 2010 and headquartered in Paris, France, with an additional office in Irvine, California, the company focuses on providing a minimally invasive prosthetic mitral valve that can be implanted on a beating heart. This approach preserves the native valve structure and respects the surrounding anatomy, ensuring reduced trauma during surgical procedures. HighLife's technology is designed for ease and safety of use, as well as optimal treatment outcomes, allowing for delivery through a transseptal passage via the femoral vein. The system is currently undergoing clinical evaluation to assess its effectiveness in addressing severe heart conditions.
Synthace Limited is a company that develops software and processes aimed at enhancing productivity in biosciences across various industries, including health, pharmaceuticals, food, energy, agri-science, and manufacturing. Central to its offerings is Antha, a cloud-based platform designed to automate and improve biological processes. Antha allows users to visually design, execute, and analyze biological workflows, linking lab equipment, protocols, and processes to enable repeatable and efficient development. Founded in 2011 and headquartered in London, with an additional location in Cambridge, Massachusetts, Synthace also maintains a strategic partnership with Microsoft to further its mission of increasing bioscience productivity and facilitating better engineering of biological systems.
Biotalys is a green biotech company that employs its proprietary Agrobody technology platform to develop crop protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combine the high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications. It was incorporated in 2012 and is based in Ghent, Belgium.
Breath Therapeutics GmbH, based in Munich, Germany, with an additional office in Menlo Park, California, develops innovative drug-aerosol therapeutics aimed at treating bronchiolitis obliterans syndrome and other severe respiratory diseases. Founded in 2016 and now a subsidiary of Zambon S.p.A., the company focuses on combining novel formulations of existing drugs with advanced inhalation technologies. Their products include a liposomal formulation of cyclosporine A designed for inhalation, paired with a high-performance nebulizer that optimizes drug delivery. This approach allows for rapid delivery of high drug concentrations directly to the lungs, enhancing the efficacy of treatments while reducing systemic exposure. Breath Therapeutics aims to address significant unmet medical needs in rare pulmonary conditions through its targeted inhalation therapies.
HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment. The company's platform helps to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery enabling patients to get treatment against several diseases.
myTomorrows is a healthcare information platform that facilitates access to innovative drugs in development for patients and physicians who are often excluded from clinical trials. The company focuses on areas with significant unmet medical needs, including oncology, neurology, psychiatry, and rare diseases. By identifying promising treatments and gathering relevant information, myTomorrows informs both patients and healthcare providers about available drug options. The platform enables users to request access to these innovative therapies, thereby improving the chances for patients to receive potentially life-saving treatments that are otherwise difficult to obtain.
Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immune-therapeutics for infectious diseases and cancers using its proprietary arenavirus platform. The company's key platforms, Vaxwave and TheraT, aim to elicit robust immune responses, including high levels of neutralizing antibodies and T cells, which are often lacking in traditional therapies. Hookipa's product pipeline features HB-101, a vaccine targeting cytomegalovirus, and HB-201 and HB-202, which are in preclinical studies for human papillomavirus-positive cancers. Additionally, the company is collaborating with Gilead Sciences to create therapies for chronic Hepatitis B and HIV infections. Founded in 2011 and headquartered in New York, Hookipa Pharma aims to transform the field of immunotherapy through its innovative approaches.
Shockwave Medical, Inc. is a medical device company that specializes in intravascular lithotripsy technology aimed at treating calcified plaque in patients with various cardiovascular diseases. The company has developed the Lithoplasty™ family of balloon dilatation catheters, which incorporate lithotripsy electrodes to enhance the compliance of rigid vascular and valvular lesions before low-pressure dilation. This approach minimizes injury to healthy tissue and addresses limitations associated with traditional revascularization technologies. Shockwave offers specific catheters for different applications, including M5 catheters for above-the-knee peripheral artery disease, C2 catheters for coronary artery disease, and S4 catheters for below-the-knee peripheral artery disease. The technology is designed to facilitate more effective angioplasty and improve stent delivery, as well as enhance native tissue preparation for trans-catheter aortic valve replacement. Founded in 2009 and headquartered in Santa Clara, California, Shockwave Medical serves interventional cardiologists, vascular surgeons, and interventional radiologists across the United States and internationally.
iOmx Therapeutics AG is a Munich-based company specializing in immuno-oncology target discovery and drug development. The company focuses on creating innovative cancer therapeutics that target novel immune checkpoint modulators present on tumor cells. By employing a systematic screening approach of human tumor cells, iOmx has identified several new targets and studied their mechanisms of action. The foundation of its research is based on the principles of cancer immune-checkpoint therapy, which aims to overcome the natural resistance of tumors to immune responses. This resistance is often facilitated by cell surface molecules that activate immune-inhibitory receptors on T cells. By neutralizing these inhibitory interactions, iOmx Therapeutics seeks to reactivate the host immune response, thereby enhancing the effectiveness of cancer treatments.
Delinia, Inc. is a biotechnology company based in San Francisco, California, dedicated to developing innovative therapeutics for autoimmune and inflammatory diseases. Founded in 2014, Delinia's primary focus is on a lead program that involves a molecule designed to selectively potentiate and expand regulatory T cells (Tregs), which play a vital role in maintaining self-tolerance and immune system balance. The company's scientific founders and experienced leadership team are committed to advancing its therapeutic programs toward clinical application. As of 2017, Delinia operates as a subsidiary of Celgene Corporation.
Inspirna is a biopharmaceutical company focused on discovering and developing innovative therapeutic targets and drugs for various cancer subtypes, including melanoma, colorectal cancer, and triple-negative breast cancer. Utilizing a proprietary microRNA-based target discovery platform, Inspirna identifies and validates novel post-transcriptionally regulated targets, leading to the creation of first-in-class therapeutics. The company has developed several promising drug candidates, such as RGX-104, an oral small molecule designed for treating solid tumors, RGX-202, which targets cancer metabolism in gastrointestinal cancers, and RGX-019, a monoclonal antibody aimed at disrupting pathways that promote tumor progression and metastasis. Founded in 2010 and headquartered in New York, Inspirna strives to transform the lives of cancer patients by providing safe and effective therapies for metastatic disease.
RefleXion Medical Inc. specializes in developing a biologically-guided radiotherapy system aimed at transforming cancer treatment. The company’s innovative technology allows tumors to continuously signal their location during therapy, facilitating the simultaneous treatment of multiple tumors, particularly in cases of metastasis. The RefleXion X1 machine is currently cleared for various forms of radiotherapy, including stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT). At the core of RefleXion's approach is the integration of positron-emission tomography (PET) imaging, which enables real-time tumor tracking and dose adaptation based on the biological characteristics of the tumors. This advancement in radiotherapy promises to enhance precision in cancer treatment, offering a potential paradigm shift in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic collaborations, including partnerships with Telix Pharmaceuticals and HealthMyne.
MedDay is an international biopharmaceutical company dedicated to developing treatments for neurodegenerative diseases by targeting key neurometabolic pathways. Established in 2016, the company is focused on creating disease-modifying therapies that aim to repair and protect the nervous system. By investigating brain metabolism, MedDay seeks to address significant unmet medical needs and improve patient care for those affected by these disorders. The promising outcomes from their clinical trials motivate the company to continue exploring innovative treatment options, ultimately striving to enhance the quality of life for patients and their caregivers in the healthcare community.
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid development and the commercialization of revolutionary biodegradable sealants and adhesives for wound closure in the field of surgery, with a key focus on minimally invasive surgery. TISSIUM is developing products that are non-toxic, bind strongly to tissues and deliver ‘on-demand’ wound closure within the ‘wet’ and dynamic environments in the body. The Company’s technology and products are based on world-class research and intellectual property from the laboratories of Robert Langer (MIT) and Jeff Karp (Brigham & Women’s Hospital). Gecko was founded in 2013 and is backed by leading healthcare investors Omnes Capital, CM-CIC and CapDecisif Manangement.
Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, focused on developing precision therapies for cardiovascular and renal conditions. Established in 2014, the company operates as a subsidiary of Novo Nordisk A/S. Corvidia specializes in researching and commercializing innovative treatments for chronic kidney disease, atherosclerotic cardiovascular disease, inflammation, and high triglyceride-induced acute pancreatitis. By identifying patients with unique sensitivities to specific biological pathways, Corvidia aims to advance the development of transformative therapies that address the complex interplay between cardiovascular and renal health.
MISSION Therapeutics Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small-molecule drugs that selectively target deubiquitylating enzymes (DUBs). The company's pipeline includes promising candidates such as USP30, which is aimed at treating Parkinson's disease and cancer, and USP7, which is recognized as a significant target in oncology. In addition to these, MISSION Therapeutics has various DUB programs that address conditions in oncology, neurodegeneration, rare mitochondrial diseases, kidney disease, and inflammation. Founded in 2011, the company is actively engaged in advancing its innovative drug development platform, which capitalizes on the ubiquitin pathway to enhance protein homeostasis and offers potential therapeutic options in several challenging medical areas.
ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, focused on drug discovery and development for acute and chronic viral infections. Founded in 2014 by a group of scientists from the Infectiology Research Center, the company has established a unique platform to identify intracellular therapeutic targets and molecules, particularly for human pathogens. ENYO Pharma is developing treatments for significant viral infections, with ongoing programs targeting chronic hepatitis B and severe influenza. Its lead compound, EYP001, is designed to modulate FXR and reduce viral replication, while EYP002 is currently undergoing preclinical studies. The company aims to advance its pipeline into Phase II clinical trials and collaborates closely with research institutions to leverage innovative therapeutic strategies. ENYO Pharma is committed to addressing unmet medical needs in infectious and metabolic diseases, positioning itself as a leader in antiviral therapies.
ObsEva SA is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to developing innovative therapeutics for women's reproductive health and pregnancy. Founded in 2012 by Ernest Loumaye and André Chollet, the company focuses on addressing serious conditions such as endometriosis, heavy menstrual bleeding, and preterm labor. Its key products include Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist aimed at treating pain from endometriosis and uterine fibroids, and OBE022, a selective prostaglandin F2α receptor antagonist designed for once-daily treatment of preterm labor. Additionally, ObsEva is advancing Nolasiban, an oral oxytocin receptor antagonist intended to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company operates primarily in Switzerland and is committed to improving outcomes for women facing reproductive health challenges.
Asceneuron SA is a biotechnology company based in Lausanne, Switzerland, founded in 2012, that focuses on discovering and developing therapeutics for neurodegenerative disorders with significant unmet medical needs. The company targets conditions such as progressive supranuclear palsy, orphan tauopathies, Alzheimer’s disease, and Parkinson’s disease. Asceneuron aims to develop orally bioavailable small molecule drugs that address both symptomatic relief and disease progression for these debilitating conditions. Tauopathies, characterized by the accumulation of tau protein deposits in the brain, are a key area of focus, as they currently lack effective treatments. With the increasing prevalence of Alzheimer's disease posing a major healthcare challenge, Asceneuron aspires to become a leading entity in the biotech sector by providing innovative and more effective therapeutic options for patients suffering from neurodegenerative diseases. The company operates as a subsidiary of Merck KGaA.
Shockwave Medical, Inc. is a medical device company that specializes in intravascular lithotripsy technology aimed at treating calcified plaque in patients with various cardiovascular diseases. The company has developed the Lithoplasty™ family of balloon dilatation catheters, which incorporate lithotripsy electrodes to enhance the compliance of rigid vascular and valvular lesions before low-pressure dilation. This approach minimizes injury to healthy tissue and addresses limitations associated with traditional revascularization technologies. Shockwave offers specific catheters for different applications, including M5 catheters for above-the-knee peripheral artery disease, C2 catheters for coronary artery disease, and S4 catheters for below-the-knee peripheral artery disease. The technology is designed to facilitate more effective angioplasty and improve stent delivery, as well as enhance native tissue preparation for trans-catheter aortic valve replacement. Founded in 2009 and headquartered in Santa Clara, California, Shockwave Medical serves interventional cardiologists, vascular surgeons, and interventional radiologists across the United States and internationally.
Recor Medical, Inc. is a clinical-stage medical device company based in Palo Alto, California, specializing in the development of a therapeutic non-focused ultrasound system for renal denervation in patients with resistant hypertension. The company’s primary offering, the PARADISE technology, features a percutaneous renal denervation system that utilizes a six French catheter equipped with a cylindrical transducer. This system emits ultrasound energy circumferentially to facilitate an efficient renal denervation procedure. By combining high-intensity ultrasound energy with water-based cooling of the renal artery, the technology aims to reduce the over-activity of renal nerves, ultimately lowering blood pressure in patients. ReCor Medical's products are distributed through dealers in Scandinavia, Northern Europe, and Italy. Founded in 2009, the company operates as a subsidiary of Otsuka Holdings Co., Ltd. following a transaction announced in July 2018.
Synthace Limited is a company that develops software and processes aimed at enhancing productivity in biosciences across various industries, including health, pharmaceuticals, food, energy, agri-science, and manufacturing. Central to its offerings is Antha, a cloud-based platform designed to automate and improve biological processes. Antha allows users to visually design, execute, and analyze biological workflows, linking lab equipment, protocols, and processes to enable repeatable and efficient development. Founded in 2011 and headquartered in London, with an additional location in Cambridge, Massachusetts, Synthace also maintains a strategic partnership with Microsoft to further its mission of increasing bioscience productivity and facilitating better engineering of biological systems.
myTomorrows is a healthcare information platform that facilitates access to innovative drugs in development for patients and physicians who are often excluded from clinical trials. The company focuses on areas with significant unmet medical needs, including oncology, neurology, psychiatry, and rare diseases. By identifying promising treatments and gathering relevant information, myTomorrows informs both patients and healthcare providers about available drug options. The platform enables users to request access to these innovative therapies, thereby improving the chances for patients to receive potentially life-saving treatments that are otherwise difficult to obtain.
Crescendo Biologics Limited is a Cambridge-based company focused on developing innovative therapies for oncology and dermatology, particularly through small molecules and monoclonal antibodies. The company specializes in multi-specific immune-oncology modulators and Humabody Drug Conjugates, leveraging a proprietary transgenic mouse platform that facilitates the in vivo maturation of human VH domains. This technology allows Crescendo to optimize the affinity and biophysical properties of its Humabodies, which are small antibody fragments retaining essential binding capabilities. By addressing challenges in generating high-affinity, soluble human VH antibody fragments, Crescendo aims to develop potent, multi-functional therapeutics. The company engages in both in-house product development and partnerships with other organizations to expand its impact in the field of antibody therapeutics. Established in 2007, Crescendo Biologics was originally named Translocus Limited before rebranding in 2009.
RefleXion Medical Inc. specializes in developing a biologically-guided radiotherapy system aimed at transforming cancer treatment. The company’s innovative technology allows tumors to continuously signal their location during therapy, facilitating the simultaneous treatment of multiple tumors, particularly in cases of metastasis. The RefleXion X1 machine is currently cleared for various forms of radiotherapy, including stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT). At the core of RefleXion's approach is the integration of positron-emission tomography (PET) imaging, which enables real-time tumor tracking and dose adaptation based on the biological characteristics of the tumors. This advancement in radiotherapy promises to enhance precision in cancer treatment, offering a potential paradigm shift in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic collaborations, including partnerships with Telix Pharmaceuticals and HealthMyne.
NuCana plc is a clinical-stage biopharmaceutical company based in Edinburgh, United Kingdom, specializing in the development of advanced treatments for cancer. Utilizing its proprietary ProTide technology, NuCana aims to enhance the efficacy and safety of existing chemotherapy agents. The company's lead product candidate, Acelarin, is currently undergoing multiple clinical trials, including Phase III trials for biliary tract and metastatic pancreatic cancers, as well as Phase II trials for platinum-resistant ovarian cancer. Additionally, NuCana is advancing NUC-3373 and NUC-7738, both of which are in Phase I clinical trials targeting advanced solid tumors and hematological malignancies. The company collaborates with Cardiff University and its affiliated consultants to further its research and development efforts. Established in 1997, NuCana has shifted its focus towards addressing significant unmet medical needs in oncology, supported by a management team with extensive experience in building successful biopharmaceutical ventures.
ProQR Therapeutics N.V. is a biopharmaceutical company focused on the discovery and development of RNA-based therapeutics aimed at treating genetic disorders. The company is advancing several key product candidates, including sepofarsen, currently in a phase II/III trial for Leber’s congenital amaurosis type 10, and QR-421a, which is in a phase 1/2 trial for Usher syndrome type 2 and non-syndromic retinitis pigmentosa. Additionally, QR-1123 is in a phase 1/2 trial for autosomal dominant retinitis pigmentosa, while QR-504a is undergoing its first clinical trial for Fuchs endothelial corneal dystrophy. ProQR Therapeutics has established collaboration agreements with prominent institutions such as General Hospital Corporation and Radboud University Medical Center. Founded in 2012, the company is headquartered in Leiden, the Netherlands.
Inotrem S.A. is a biotechnology company based in Paris, France, specializing in the discovery and development of innovative treatments for inflammatory pathologies, particularly in critical care settings. Founded in 2013, the company focuses on immunotherapy and has created a novel immunomodulation approach targeting the TREM-1 pathway to manage excessive inflammation. Its lead product, nangibotide (also known as LR12), is a first-in-class TREM-1 inhibitor designed to address severe conditions such as septic shock and myocardial infarction. Inotrem is also advancing a program aimed at treating chronic inflammatory diseases, leveraging its proprietary technology platform to develop new therapeutic modalities.
Shockwave Medical, Inc. is a medical device company that specializes in intravascular lithotripsy technology aimed at treating calcified plaque in patients with various cardiovascular diseases. The company has developed the Lithoplasty™ family of balloon dilatation catheters, which incorporate lithotripsy electrodes to enhance the compliance of rigid vascular and valvular lesions before low-pressure dilation. This approach minimizes injury to healthy tissue and addresses limitations associated with traditional revascularization technologies. Shockwave offers specific catheters for different applications, including M5 catheters for above-the-knee peripheral artery disease, C2 catheters for coronary artery disease, and S4 catheters for below-the-knee peripheral artery disease. The technology is designed to facilitate more effective angioplasty and improve stent delivery, as well as enhance native tissue preparation for trans-catheter aortic valve replacement. Founded in 2009 and headquartered in Santa Clara, California, Shockwave Medical serves interventional cardiologists, vascular surgeons, and interventional radiologists across the United States and internationally.
Crescendo Biologics Limited is a Cambridge-based company focused on developing innovative therapies for oncology and dermatology, particularly through small molecules and monoclonal antibodies. The company specializes in multi-specific immune-oncology modulators and Humabody Drug Conjugates, leveraging a proprietary transgenic mouse platform that facilitates the in vivo maturation of human VH domains. This technology allows Crescendo to optimize the affinity and biophysical properties of its Humabodies, which are small antibody fragments retaining essential binding capabilities. By addressing challenges in generating high-affinity, soluble human VH antibody fragments, Crescendo aims to develop potent, multi-functional therapeutics. The company engages in both in-house product development and partnerships with other organizations to expand its impact in the field of antibody therapeutics. Established in 2007, Crescendo Biologics was originally named Translocus Limited before rebranding in 2009.
MISSION Therapeutics Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small-molecule drugs that selectively target deubiquitylating enzymes (DUBs). The company's pipeline includes promising candidates such as USP30, which is aimed at treating Parkinson's disease and cancer, and USP7, which is recognized as a significant target in oncology. In addition to these, MISSION Therapeutics has various DUB programs that address conditions in oncology, neurodegeneration, rare mitochondrial diseases, kidney disease, and inflammation. Founded in 2011, the company is actively engaged in advancing its innovative drug development platform, which capitalizes on the ubiquitin pathway to enhance protein homeostasis and offers potential therapeutic options in several challenging medical areas.